高级检索
当前位置: 首页 > 详情页

Hydrogen inhalation attenuated bleomycin-induced pulmonary fibrosis by inhibiting transforming growth factor-beta 1 and relevant oxidative stress and epithelial-to-mesenchymal transition

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China [2]Department of Pulmonary and Critical Care Medicine, InnerMongolia Autonomous Region People’s Hospital, Hohhot, China [3]Department of Pulmonary and Critical Care Medicine, Center of RespiratoryMedicine, China–Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China [4]Department of RespiratoryMedicine, Zhengzhou Central Hospital, Zhengzhou, China
出处:
ISSN:

关键词: bleomycin-induced pulmonary fibrosis epithelial-to-mesenchymal transition hydrogen inhalation oxidative stress TGF-beta 1 expression

摘要:
New Findings What is the central question of this study?The aim was to explore the effects and underlying mechanisms of H-2 on bleomycin-induced pulmonary fibrosis. What are the main findings and its importance?Our results indicate that, in bleomycin-induced pulmonary fibrosis, H-2 inhalation attenuated oxidative stress and reversed the pulmonary epithelial-to-mesenchymal transition process by reducing reactive oxygen species production and inhibiting the expression of transforming growth factor-beta 1, alpha-smooth muscle actin and collagen I to improve fibrotic injury and exert anti-fibrogenic effects. Thus, H-2 inhalation has promising therapeutic potential as a useful adjuvant treatment for patients with idiopathic pulmonary fibrosis, which deserves further study and evaluation. center dot center dot Hydrogen (H-2) can protect against tissue damage. The effect of H-2 inhalation therapy on the pathogenesis of pulmonary fibrosis remains unknown. This study was designed to explore the effects and underlying mechanisms of H-2 inhalation on bleomycin (BLM)-induced pulmonary fibrosis. A rat model of pulmonary fibrosis was established with BLM. Rats were randomly divided into control and H-2 inhalation groups. Haematoxylin and Eosin staining and Mason's Trichrome staining were performed to evaluate pulmonary fibrosis injury, inflammatory cell infiltration, structural disorder and collagen deposition. qRT-PCR and western blot assays were used to determine the expression of TNF-alpha, TGF-beta 1, alpha-SMA, E-cadherin, N-cadherin, vimentin, VEGF and collagen type I at both mRNA and protein levels. The contents of reactive oxygen species, TGF-beta 1, TNF-alpha, malondialdehyde and hydroxyproline were determined with biochemical test kits or ELISA kits. Bleomycin-stimulated rats exhibited typical symptoms of pulmonary fibrosis, which featured an increase in collagen deposition, alveolitis, fibrosis and parenchymal structural disorder in the lung. However, BLM-induced oxidative stress was attenuated by H-2 inhalation therapy, which reduced the contents of reactive oxygen species, malondialdehyde and hydroxyproline, enhanced the activity of glutathione peroxidase and decreased the expression of TGF-beta 1 and TNF-alpha. In addition, H-2 inhalation also inhibited BLM-induced epithelial-to-mesenchymal transition by inhibiting TGF-beta 1, increasing the expression level of the epithelial cell marker E-cadherin, and decreasing the expression level of the mesenchymal cell marker vimentin in a time-dependent manner. In addition, H-2 inhalation downregulated alpha-SMA expression and suppressed collagen I generation, exerting anti-fibrogenic effects. Hydrogen inhalation therapy attenuates BLM-induced pulmonary fibrosis by inhibiting TGF-beta 1, relevant oxidative stress and epithelial-to-mesenchymal transition.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 生理学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 生理学
JCR分区:
出版当年[2017]版:
Q2 PHYSIOLOGY
最新[2023]版:
Q2 PHYSIOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2017版] 出版当年五年平均[2013-2017] 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China [2]Department of Pulmonary and Critical Care Medicine, InnerMongolia Autonomous Region People’s Hospital, Hohhot, China
通讯作者:
通讯机构: [1]Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China [3]Department of Pulmonary and Critical Care Medicine, Center of RespiratoryMedicine, China–Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China [*1]China–Japan Friendship Hospital International Department No. 2 East Yinghua Street, Chaoyang District,Beijing 100029. OrBeijing Chao-Yang Hospital, 8Gongren Tiyuchang Nanlu, Chaoyang District,Beijing, 100020.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)